BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 9166489)

  • 21. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
    DeVore RF; Jagasia M; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-27-S12-29. PubMed ID: 9331116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
    Maier-Lenz H; Hauns B; Haering B; Koetting J; Mross K; Unger C; Bauknecht T; du Bois A; Meerpohl HG; Hollaender N; Diergarten K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-16-S19-19. PubMed ID: 9427259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
    Hainsworth JD; Thompson DS; Greco FA
    J Clin Oncol; 1995 Jul; 13(7):1609-14. PubMed ID: 7602349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-agent paclitaxel as a 3-hour infusion.
    Gatzemeier U; Neuhauss R; Schluter I; von Pawel J; Wagner H; Diergarten K
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):94-7. PubMed ID: 9007132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-14-S12-17. PubMed ID: 9331113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-hour paclitaxel infusions: review of safety and efficacy.
    Greco FA; Thomas M; Hainsworth JD
    Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
    Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL
    Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
    Charoentum C; Thongprasert S; Chewasakulyong B
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1603-7. PubMed ID: 17940374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
    Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.
    Sekine I; Nishiwaki Y; Watanabe K; Yoneda S; Saijo N
    Clin Cancer Res; 1996 Jun; 2(6):941-5. PubMed ID: 9816254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H; Guan Z; Lin T
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.